Singapore Medical Group reviewing current and future acquisitions strategies
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
CATALIST-LISTED Singapore Medical Group (SMG) said that it is undertaking a review of its current and future acquisitions strategies, it said in a filing with the Singapore Exchange (SGX) on Monday evening.
Without identifying what specifically prompted this filing, the group said that in the recent course of work, through dialogues with the professional governing body and professional doctors, its management's attention has been drawn to the Singapore Medical Council's ethical code and ethical guidelines (ECEG).
In particular, SMG highlighted that the ECEG states that doctors must always place patients' best interests above their personal interests and any business or financial considerations.
The group added that it would make further announcements as and when there are material updates or developments.
"Each case will be judged by its particular facts and circumstances," the group said.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Singaporeans can now buy record amount of yen per Singdollar
